TipRanks
1 min read
In This Article:
Morgan Stanley analyst David Bailey keeps an Overweight rating on ResMed (RMD) with a $286 price target after Apnimed provided topline results as part of its Phase 3 trial for AD109, focused on the treatment of obstructive sleep apnea. Participants treated with AD109 recorded a mean Apnea-Hypopnea Index reduction of 55.6% from baseline, the analyst tells investors in a research note. The firm believes AD109 appears to focus on patients who are unable or refuse to tolerate continuous positive airway pressure, or CPAP. Further, patients who record an AHI less than 10 appear to be those with mild to moderate sleep apnea, the analyst tells investors in a research note. On balance, Morgan Stanley sees a “modest” potential earnings impact for ResMed based on current data from Apnimed.
-
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
-
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. >;elm:context_link;itc:0;sec:content-canvas" href="https://thefly.com/?utm_source=finance.yahoo.com&utm_medium=referral" rel="nofollow noopener" target="_blank">Try Now>>
Read More on RMD:
Disclaimer & DisclosureReport an Issue
-
Apnimed data brings competitive threat to ResMed, says RBC Capital
-
Resmed’s Growth Potential Highlighted by Promising Trial Results and Future Opportunities
-
Buy Rating for Resmed: Positive Phase 3 Trial Results and Market Conditions Boost AD109’s Appeal
-
GOOGL, RMD: TipRanks’ New AI Analyst Tool Reveals 2 Stocks for Potential Growth
-
ResMed named Sleep Partner of the Qatar Airways British & Irish Lions Tour
